购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空
筛选
已筛选:全部清除
TargetMol | Tags 通过 靶点 筛选
  • Cholecystokinin Receptor
    (2)
  • Others
    (1)
TargetMol | Tags 通过 货期 筛选
  • 现货
    (3)
  • 5日内发货
    (3)
筛选
搜索结果
TargetMol产品目录中 "

cck 5

"的结果
  • 抑制剂&激动剂
    4
    TargetMol | Inhibitors_Agonists
  • 化合物库
    1
    TargetMol | Compound_Libraries
  • 重组蛋白
    1
    TargetMol | Recombinant_Protein
  • 多肽产品
    2
    TargetMol | Peptide_Products
  • 天然产物
    1
    TargetMol | Natural_Products
  • 试剂盒
    2
    TargetMol | Reagent_Kits
  • Cholecystokinin pentapeptide
    CCK-5,Gly-trp-met-asp-phe-NH2
    TP237618917-24-3
    Cholecystokinin pentapeptide is a peptide hormone of the gastrointestinal system responsible for stimulating the digestion of fat and protein.
    • 待询
    规格
    数量
  • gv-150013x
    (S)-1-(1-(adamantan-1-ylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-3-phenylurea
    T27503L151386-96-8In house
    GV-150013X ((S)-1-(1-(adamantan-1-ylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-3-phenylurea) 是一种有效的CCKB 拮抗剂,pKi= 9.02。
    • ¥ 828
    现货
    规格
    数量
    TargetMol | Inhibitor Sale
  • Ceruletide Ammonium acetate
    FI-6934 Ammonium acetate, Ceruletide Ammonium acetate (17650-98-5 free base), Caerulein Ammonium acetate
    T14932L
    Ceruletide Ammonium acetate (FI-6934 Ammonium acetate) 是一种胆囊收缩素 (CCK) 受体激动剂。它是一种安全有效的胆囊动力剂和小肠和胰腺外分泌兴奋剂。
    • ¥ 2730
    期货
    规格
    数量
  • Givinostat
    T36629497833-27-9
    Givinostat (ITF-2357) is a HDAC inhibitor with an IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively. Givinostat (ITF2357) suppresses total LPS-induced IL-1β production robustly compared with the reduction by ITF3056. At 25, 50, and 100 nM, Givinostat reduced IL-1β secretion more than 70%. Givinostat (ITF-2357) suppresses the production of IL-6 in PBMCs stimulated with TLR agonists as well as the combination of IL-12 plus IL-18. IL-6 secretion decreases to 50% at 50 nM Givinostat, but at 100 and 200 nM, there is no reduction[1]. As shown by the CCK-8 assay, Givinostat (ITF-2357) inhibits JS-1 cell proliferation in a concentration-dependent manner. Treatment with Givinostat ≥500 nM is associated with significant inhibition of JS-1 cell proliferation (P<0.01). Also, the cell inhibition rate significantly differs between the group cotreated with Givinostat ≥250 nM plus LPS and the group without LPS treatment (same Givinostat concentration) (P<0.05)[2]. Givinostat (ITF2357) at 10 mg kg is used as a positive control and, as expected, reduced serum TNFα by 60%. Strikingly, pretreatment of ITF3056 starting at 0.1 mg kg significantly reduces the circulating TNFα by nearly 90%. To achieve a significant increase in serum IL-1β production, a higher dose of LPS is injected (10 mg kg), and blood is collected after 4 h. Similarly, when pretreated with lower doses of Givinostat (ITF-2357) (1 or 5 mg kg), there is a 22% reduction for 1 mg kg and 40% for 5 mg kg[1]. [1]. Li S, et al. Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivo. J Biol Chem. 2015 Jan 23;290(4):2368-78. [2]. Wang YG, et al. Givinostat inhibition of hepatic stellate cell proliferation and protein acetylation. World J Gastroenterol. 2015 Jul 21;21(27):8326-39. [3]. Leoni F, et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med. 2005 Jan-Dec;11(1-12):1-15.
    • ¥ 447
    5日内发货
    规格
    数量